| Literature DB >> 30530994 |
Shouan Zhu1,2, Jianxi Zhu1,3, Gehua Zhen1, Yihe Hu3, Senbo An1,3, Yusheng Li1,3, Qin Zheng4, Zhiyong Chen5, Ya Yang5, Mei Wan1, Richard Leroy Skolasky1, Yong Cao1, Tianding Wu1, Bo Gao1, Mi Yang1, Manman Gao1, Julia Kuliwaba6, Shuangfei Ni1, Lei Wang1, Chuanlong Wu1, David Findlay6, Holger K Eltzschig7, Hong Wei Ouyang2,8, Janet Crane1, Feng-Quan Zhou1, Yun Guan5, Xinzhong Dong4, Xu Cao1.
Abstract
Joint pain is the defining symptom of osteoarthritis (OA) but its origin and mechanisms remain unclear. Here, we investigated an unprecedented role of osteoclast-initiated subchondral bone remodeling in sensory innervation for OA pain. We show that osteoclasts secrete netrin-1 to induce sensory nerve axonal growth in subchondral bone. Reduction of osteoclast formation by knockout of receptor activator of nuclear factor kappa-B ligand (Rankl) in osteocytes inhibited the growth of sensory nerves into subchondral bone, dorsal root ganglion neuron hyperexcitability, and behavioral measures of pain hypersensitivity in OA mice. Moreover, we demonstrated a possible role for netrin-1 secreted by osteoclasts during aberrant subchondral bone remodeling in inducing sensory innervation and OA pain through its receptor DCC (deleted in colorectal cancer). Importantly, knockout of Netrin1 in tartrate-resistant acid phosphatase-positive (TRAP-positive) osteoclasts or knockdown of Dcc reduces OA pain behavior. In particular, inhibition of osteoclast activity by alendronate modifies aberrant subchondral bone remodeling and reduces innervation and pain behavior at the early stage of OA. These results suggest that intervention of the axonal guidance molecules (e.g., netrin-1) derived from aberrant subchondral bone remodeling may have therapeutic potential for OA pain.Entities:
Keywords: Bone Biology; Innervation; Neuroscience; Osteoarthritis; Pain
Mesh:
Substances:
Year: 2019 PMID: 30530994 PMCID: PMC6391093 DOI: 10.1172/JCI121561
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808